Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) dropped 2.8% on Friday . The stock traded as low as $5.87 and last traded at $6.00, with a volume of 1,233,189 shares trading hands. The stock had previously closed at $6.17.

FOLD has been the topic of several analyst reports. Chardan Capital raised their target price on shares of Amicus Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, April 12th. Bank of America Corp. initiated coverage on shares of Amicus Therapeutics in a report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 target price on the stock. Robert W. Baird initiated coverage on shares of Amicus Therapeutics in a report on Wednesday, April 13th. They issued a “neutral” rating and a $9.00 target price on the stock. Goldman Sachs Group Inc. initiated coverage on shares of Amicus Therapeutics in a report on Wednesday, March 30th. They issued a “neutral” rating and a $10.00 target price on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $19.00 target price (up previously from $17.00) on shares of Amicus Therapeutics in a report on Tuesday, June 14th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $12.88.

The firm has a 50 day moving average price of $6.29 and a 200-day moving average price of $7.12. The company’s market cap is $762.29 million.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.01. Equities analysts expect that Amicus Therapeutics Inc. will post ($1.35) EPS for the current year.

In other Amicus Therapeutics news, General Counsel Ellen Rosenberg bought 15,000 shares of the business’s stock in a transaction on Thursday, June 2nd. The shares were bought at an average cost of $7.67 per share, with a total value of $115,050.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several institutional investors have made changes to their positions in the stock. Nationwide Fund Advisors raised its position in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock worth $1,024,000 after buying an additional 1,754 shares during the last quarter. TD Asset Management Inc. raised its position in shares of Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock worth $1,733,000 after buying an additional 2,600 shares during the last quarter. Swiss National Bank raised its position in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 5,100 shares during the last quarter. California Public Employees Retirement System raised its position in shares of Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock worth $3,163,000 after buying an additional 11,600 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 15,789 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.